O	0	9	Targeting	Target	VBG	B-VP
O	10	11	a	a	DT	B-NP
B-Cancer	12	17	tumor	tumor	NN	I-NP
O	17	18	-	-	HYPH	B-NP
O	18	26	specific	specific	JJ	I-NP
O	27	34	laminin	laminin	NN	I-NP
O	35	41	domain	domain	NN	I-NP
O	42	50	critical	critical	JJ	B-ADJP
O	51	54	for	for	IN	B-PP
O	55	60	human	human	JJ	B-NP
O	61	75	carcinogenesis	carcinogenesis	NN	I-NP
O	75	76	.	.	.	O

O	78	85	Laminin	Laminin	NN	B-NP
O	85	86	-	-	HYPH	O
O	86	89	332	332	CD	B-NP
O	90	92	is	be	VBZ	B-VP
O	93	101	critical	critical	JJ	B-ADJP
O	102	105	for	for	IN	B-PP
B-Cancer	106	114	squamous	squamous	JJ	B-NP
I-Cancer	115	119	cell	cell	NN	I-NP
I-Cancer	120	129	carcinoma	carcinoma	NN	I-NP
O	130	131	(	(	(	O
B-Cancer	131	134	SCC	SCC	NN	B-NP
O	134	135	)	)	)	O
O	136	149	tumorigenesis	tumorigenesis	NN	B-NP
O	149	150	,	,	,	O
O	151	154	but	but	CC	O
O	155	164	targeting	target	VBG	B-VP
O	165	167	it	it	PRP	B-NP
O	168	171	for	for	IN	B-PP
B-Cancer	172	178	cancer	cancer	NN	B-NP
O	179	186	therapy	therapy	NN	I-NP
O	187	190	has	have	VBZ	B-VP
O	191	195	been	be	VBN	I-VP
O	196	208	unachievable	unachievable	JJ	B-ADJP
O	209	212	due	due	JJ	B-PP
O	213	215	to	to	TO	B-PP
O	216	219	key	key	JJ	B-NP
O	220	224	role	role	NN	I-NP
O	225	227	of	of	IN	B-PP
O	228	235	laminin	laminin	NN	B-NP
O	235	236	-	-	HYPH	B-NP
O	236	239	332	332	CD	I-NP
O	240	242	in	in	IN	B-PP
O	243	252	promoting	promote	VBG	B-VP
B-Tissue	253	259	tissue	tissue	NN	B-NP
O	260	269	integrity	integrity	NN	I-NP
O	269	270	.	.	.	O

O	271	275	Here	Here	RB	B-ADVP
O	275	276	,	,	,	O
O	277	279	we	we	PRP	B-NP
O	280	284	show	show	VBP	B-VP
O	285	289	that	that	IN	B-SBAR
O	290	291	a	a	DT	B-NP
O	292	299	portion	portion	NN	I-NP
O	300	302	of	of	IN	B-PP
O	303	310	laminin	laminin	NN	B-NP
O	310	311	-	-	HYPH	B-NP
O	311	314	332	332	CD	I-NP
O	314	315	,	,	,	O
O	316	322	termed	term	VBN	B-VP
O	323	326	G45	G45	NN	B-NP
O	326	327	,	,	,	O
O	328	333	which	which	WDT	B-NP
O	334	336	is	be	VBZ	B-VP
O	337	352	proteolytically	proteolytically	RB	I-VP
O	353	360	removed	remove	VBN	I-VP
O	361	364	and	and	CC	O
O	365	371	absent	absent	JJ	B-ADJP
O	372	374	in	in	IN	B-PP
O	375	381	normal	normal	JJ	B-NP
B-Tissue	382	389	tissues	tissue	NNS	I-NP
O	389	390	,	,	,	O
O	391	393	is	be	VBZ	B-VP
O	394	405	prominently	prominently	RB	I-VP
O	406	415	expressed	express	VBN	I-VP
O	416	418	in	in	IN	B-PP
O	419	423	most	most	JJS	B-NP
O	424	429	human	human	JJ	I-NP
B-Cancer	430	433	SCC	SCC	NN	I-NP
I-Cancer	434	440	tumors	tumor	NNS	I-NP
O	441	444	and	and	CC	O
O	445	450	plays	play	VBZ	B-VP
O	451	453	an	an	DT	B-NP
O	454	463	important	important	JJ	I-NP
O	464	468	role	role	NN	I-NP
O	469	471	in	in	IN	B-PP
O	472	477	human	human	JJ	B-NP
B-Cancer	478	481	SCC	SCC	NN	I-NP
O	482	495	tumorigenesis	tumorigenesis	NN	I-NP
O	495	496	.	.	.	O

O	497	504	Primary	Primary	JJ	B-NP
O	505	510	human	human	JJ	I-NP
B-Cell	511	524	keratinocytes	keratinocyte	NNS	I-NP
I-Cell	525	532	lacking	lack	VBG	B-VP
I-Cell	533	536	G45	G45	NN	B-NP
O	537	538	(	(	(	O
B-Cell	538	546	DeltaG45	DeltaG45	NN	B-NP
O	546	547	)	)	)	O
O	548	554	showed	show	VBD	B-VP
O	555	566	alterations	alteration	NNS	B-NP
O	567	569	of	of	IN	B-PP
O	570	575	basal	basal	JJ	B-NP
O	576	584	receptor	receptor	NN	I-NP
O	585	597	organization	organization	NN	I-NP
O	597	598	,	,	,	O
O	599	607	impaired	impaired	JJ	B-NP
B-Cellular_component	608	614	matrix	matrix	NN	I-NP
O	615	625	deposition	deposition	NN	I-NP
O	625	626	,	,	,	O
O	627	630	and	and	CC	O
O	631	640	increased	increase	VBN	B-NP
O	641	650	migration	migration	NN	I-NP
O	650	651	.	.	.	O

O	652	657	After	After	IN	B-PP
B-Cancer	658	661	SCC	SCC	NN	B-NP
O	662	676	transformation	transformation	NN	I-NP
O	676	677	,	,	,	O
O	678	681	the	the	DT	B-NP
O	682	689	absence	absence	NN	I-NP
O	690	692	of	of	IN	B-PP
O	693	696	G45	G45	NN	B-NP
O	697	703	domain	domain	NN	I-NP
O	704	706	in	in	IN	B-PP
B-Cell	707	715	DeltaG45	DeltaG45	NN	B-NP
I-Cell	716	721	cells	cell	NNS	I-NP
O	722	725	was	be	VBD	B-VP
O	726	736	associated	associate	VBN	I-VP
O	737	741	with	with	IN	B-PP
O	742	751	deficient	deficient	JJ	B-NP
O	752	765	extracellular	extracellular	JJ	I-NP
O	766	772	signal	signal	NN	I-NP
O	772	773	-	-	HYPH	O
O	773	782	regulated	regulate	VBN	B-VP
O	783	789	kinase	kinase	NN	B-NP
O	790	793	and	and	CC	O
O	794	814	phosphotidylinositol	phosphotidylinositol	NN	B-NP
O	815	816	3	3	CD	I-NP
O	816	817	-	-	HYPH	I-NP
O	817	823	kinase	kinase	NN	I-NP
O	824	825	(	(	(	O
O	825	829	PI3K	PI3K	NN	B-NP
O	829	830	)	)	)	O
O	831	838	pathway	pathway	NN	B-NP
O	839	849	activation	activation	NN	I-NP
O	849	850	,	,	,	O
O	851	859	impaired	impaired	JJ	B-NP
O	860	868	invasion	invasion	NN	I-NP
O	868	869	,	,	,	O
O	870	879	deficient	deficient	JJ	B-NP
O	880	897	metalloproteinase	metalloproteinase	NN	I-NP
O	898	906	activity	activity	NN	I-NP
O	906	907	,	,	,	O
O	908	911	and	and	CC	O
O	912	918	absent	absent	JJ	B-NP
O	919	932	tumorgenicity	tumorgenicity	NN	I-NP
O	933	935	in	in	FW	B-ADVP
O	936	940	vivo	vivo	FW	I-ADVP
O	940	941	.	.	.	O

O	942	952	Expression	Expression	NN	B-NP
O	953	955	of	of	IN	B-PP
O	956	959	G45	G45	NN	B-NP
O	960	962	or	or	CC	O
O	963	972	activated	activate	VBN	B-NP
O	973	977	PI3K	PI3K	NN	I-NP
O	978	985	subunit	subunit	NN	I-NP
O	986	988	in	in	IN	B-PP
B-Cell	989	997	DeltaG45	DeltaG45	NN	B-NP
I-Cell	998	1003	cells	cell	NNS	I-NP
O	1004	1012	reversed	reverse	VBD	B-VP
O	1013	1018	these	these	DT	B-NP
O	1019	1032	abnormalities	abnormality	NNS	I-NP
O	1032	1033	.	.	.	O

O	1034	1037	G45	G45	NN	B-NP
O	1038	1046	antibody	antibody	NN	I-NP
O	1047	1056	treatment	treatment	NN	I-NP
O	1057	1064	induced	induce	VBD	B-VP
B-Cancer	1065	1068	SCC	SCC	NN	B-NP
I-Cancer	1069	1074	tumor	tumor	NN	I-NP
O	1075	1084	apoptosis	apoptosis	NN	I-NP
O	1084	1085	,	,	,	O
O	1086	1095	decreased	decrease	VBD	B-VP
B-Cancer	1096	1099	SCC	SCC	NN	B-NP
I-Cancer	1100	1105	tumor	tumor	NN	I-NP
O	1106	1119	proliferation	proliferation	NN	I-NP
O	1119	1120	,	,	,	O
O	1121	1124	and	and	CC	O
O	1125	1133	markedly	markedly	RB	B-NP
O	1134	1142	impaired	impaired	JJ	I-NP
O	1143	1148	human	human	JJ	I-NP
B-Cancer	1149	1152	SCC	SCC	NN	I-NP
O	1153	1166	tumorigenesis	tumorigenesis	NN	I-NP
O	1167	1169	in	in	FW	B-ADVP
O	1170	1174	vivo	vivo	FW	I-ADVP
O	1175	1182	without	without	IN	B-PP
O	1183	1192	affecting	affect	VBG	B-VP
O	1193	1199	normal	normal	JJ	B-NP
B-Tissue	1200	1206	tissue	tissue	NN	I-NP
O	1207	1215	adhesion	adhesion	NN	I-NP
O	1215	1216	.	.	.	O

O	1217	1222	These	These	DT	B-NP
O	1223	1230	results	result	NNS	I-NP
O	1231	1235	show	show	VBP	B-VP
O	1236	1237	a	a	DT	B-NP
O	1238	1248	remarkable	remarkable	JJ	I-NP
O	1249	1260	selectivity	selectivity	NN	I-NP
O	1261	1263	of	of	IN	B-PP
O	1264	1274	expression	expression	NN	B-NP
O	1275	1278	and	and	CC	O
O	1279	1287	function	function	NN	B-NP
O	1288	1291	for	for	IN	B-PP
O	1292	1299	laminin	laminin	NN	B-NP
O	1299	1300	-	-	HYPH	O
O	1300	1303	332	332	CD	B-NP
O	1304	1307	G45	G45	NN	I-NP
O	1308	1310	in	in	IN	B-PP
O	1311	1316	human	human	JJ	B-NP
B-Cancer	1317	1320	SCC	SCC	NN	I-NP
O	1321	1334	tumorigenesis	tumorigenesis	NN	I-NP
O	1335	1338	and	and	CC	O
O	1339	1348	implicate	implicate	VBP	B-VP
O	1349	1351	it	it	PRP	B-NP
O	1352	1354	as	as	IN	B-PP
O	1355	1356	a	a	DT	B-NP
O	1357	1365	specific	specific	JJ	I-NP
O	1366	1372	target	target	NN	I-NP
O	1373	1376	for	for	IN	B-PP
B-Cancer	1377	1387	anticancer	anticancer	JJ	B-NP
O	1388	1395	therapy	therapy	NN	I-NP
O	1395	1396	.	.	.	O

